More on GMAB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.5 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Genmab A/S (NQ:GMAB)
Delayed: 43.79 +3.79 (9.48%)
Prev. Close $40.00  
Open$39.84 
52 Wk High$ 
52 Wk Low$ 
Day High$44.34 
Day Low$39.64 
P/E N/A  
EPS$ 
Volume13,000,336 

Friends, Peers and Foes (?): GNMSF, GEN:DC, 0MGB, ABBV, S1GE34 (more...)

Oct 25, 2026 07:00 AM Genmab reports Phase 2 response rate data for petosemtamab in mCRC
Oct 25, 2026 07:00 AM Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Oct 24, 2026 07:00 AM Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Oct 23, 2026 12:20 PM Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
Oct 23, 2026 11:59 AM Form 6-K GENMAB A/S For: Oct 23
Oct 23, 2026 11:56 AM Genmab's Rina-S meets phase 3 endpoints in ovarian cancer trial
Oct 23, 2026 11:55 AM Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Oct 20, 2026 03:15 AM Morgan Stanley Assumes Genmab A/S (GMAB) at Equalweight
Oct 14, 2026 04:42 AM Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,100 at UBS
Oct 13, 2026 07:50 AM Form 6-K GENMAB A/S For: Oct 13
View All Articles

Entities mentioned with GMAB

View All Entities